Flow cytometric analysis confirmed these findings, revealing a 49% reduction in apoptotic rates following CSA treatment (23.21 ± 1.76% in AD/Si-GPR43 + CSA vs. 47.23 ± 3.29 in AD/Si-GPR43; p < 0.05; Fig. 8G). This evidence concerns the gene FFAR2 and Alzheimer disease.